{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:48:34Z","timestamp":1782445714045,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.bmcl.2022.128842","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T11:43:11Z","timestamp":1654515791000},"page":"128842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["WCK 4034: A promising oxazolidinone for treating gram positive infections"],"prefix":"10.1016","volume":"71","author":[{"given":"Satish","family":"Bhawsar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaji","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Yeole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Chavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manohar","family":"Nandanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Bhagwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.128842_b0005","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1086\/646432","article-title":"Methicillin-resistant S aureus in US hospitals, 1975\u20131991","volume":"13","author":"Panlilio","year":"1992","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.bmcl.2022.128842_b0010","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1056\/NEJM198704093161507","article-title":"Emergence of vancomycin resistance in coagulase-negative staphylococci","volume":"316","author":"Schwalbe","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2022.128842_b0015","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1086\/514953","article-title":"Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program","volume":"27","author":"Doern","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmcl.2022.128842_b0020","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0002-9343(94)90009-4","article-title":"Bacteremia due to viridans streptococci in neutropenic patients: a review","volume":"97","author":"Bochud","year":"1994","journal-title":"Am J Med"},{"key":"10.1016\/j.bmcl.2022.128842_b0025","first-page":"813","article-title":"Update: Staphylococcus aureus with reduced susceptibility to vancomycin\u2014United States, 1997","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.bmcl.2022.128842_b0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0732-8893(94)00147-O","article-title":"Emerging multiply resistant enterococci among clinical isolates I: prevalence data from 97 medical center surveillance studies in the United States","volume":"21","author":"Jones","year":"1995","journal-title":"Diag Microbiol Infect Dis"},{"key":"10.1016\/j.bmcl.2022.128842_b0035","doi-asserted-by":"crossref","unstructured":"Diekema DJ, Pfaller MA, Schmitz FJ, and the SENTRY Participants Group. Survey of infections due to Staphylococcus sp: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe and the Western Pacific for the SENTRY Antimicrobial Surveillance Program, 1997\u20131999. Clin Infect Dis 2001;32:S114. DOI: 10.1086\/320184.","DOI":"10.1086\/320184"},{"key":"10.1016\/j.bmcl.2022.128842_b0040","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1086\/520283","article-title":"Vancomycin-resistant enterococci","volume":"26","author":"Moellering","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmcl.2022.128842_b0045","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1128\/AAC.42.7.1762","article-title":"Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997)","volume":"42","author":"Pfaller","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 3B","key":"10.1016\/j.bmcl.2022.128842_b0050","doi-asserted-by":"crossref","first-page":"86S","DOI":"10.1016\/0002-9343(91)90349-3","article-title":"Secular trends in nosocomial primary bloodstream infections in the United States, 1980\u20131989","volume":"91","author":"Banerjee","year":"1991","journal-title":"Am J Med"},{"issue":"suppl A","key":"10.1016\/j.bmcl.2022.128842_b0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/39.suppl_1.145","article-title":"Effect of quinupristin dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteremia: comparison with a control cohort","volume":"39","author":"Linden","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmcl.2022.128842_b0060","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0966-842X(97)01032-9","article-title":"Oxazolidinones: new antibacterial agents","volume":"5","author":"Ford","year":"1997","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.bmcl.2022.128842_b0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00003495-200059010-00002","article-title":"Oxazolidinones: a review","volume":"59","author":"Diekema","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2022.128842_b0070","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/0003-4819-130-2-199901190-00012","article-title":"A novel antimicrobial agent joins the battle against resistant bacteria","volume":"130","author":"Moellering","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bmcl.2022.128842_b0075","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1128\/AAC.31.11.1791","article-title":"Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721","volume":"31","author":"Slee","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2022.128842_b0080","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1021\/jm9509556","article-title":"Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections","volume":"39","author":"Brickner","year":"1996","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmcl.2022.128842_b0085","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jac\/dkl233","article-title":"In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients","volume":"58","author":"Wilson","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bmcl.2022.128842_b0090","doi-asserted-by":"crossref","unstructured":"Gould FK. Linezolid: safety and efficacy in special populations. J Antimicrob Chemother 2011;66 Suppl 4:iv3. doi.org\/10.1093\/jac\/dkr071.","DOI":"10.1093\/jac\/dkr071"},{"key":"10.1016\/j.bmcl.2022.128842_b0095","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1592\/phco.21.11.1010.34517","article-title":"Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid","volume":"21","author":"Kuter","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"Suppl 1","key":"10.1016\/j.bmcl.2022.128842_b0100","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0163-4453(09)60009-8","article-title":"Linezolid: a review of safety and tolerability","volume":"59","author":"Vinh","year":"2009","journal-title":"J Infect"},{"key":"10.1016\/j.bmcl.2022.128842_b0105","unstructured":"Deshpande PK, Sindkhedkar MD, Phansalkar MS, Yeole RD, Gupte SV, Chugh Y, Shetty N, Bhagwat SS, Shukla MC, D\u2019Souza NJ, Patel MV. Substituted piperidine phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy. United states patent US 8,729,269 B2; 2014."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22003183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22003183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:46:07Z","timestamp":1760773567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22003183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":21,"alternative-id":["S0960894X22003183"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128842","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WCK 4034: A promising oxazolidinone for treating gram positive infections","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128842"}}